Peginterferon alfa-2a treatment of patients with HCV-related cirrhosis


 What is Hepatitis

 How is it Transmitted

 Long Term Prognosis

 Complications of HCV

 Liver Biopsy

 Treatment Info (Interferon, Herbal, etc)

 Lab Tests (PCR, Genotype,etc.)

 Nutrition & Alternative Info

 Patient Information (Support Groups, Doctor Listing, etc)

 Related Webpages

 Transplant Info

 HCV Webrings

 My guestbookbook

 Site Awards

 FAQ & Disclaimers

A second study in the New England Journal of Medicine has shown that weekly administration of peginterferon is also more effective in treating chronic hepatitis C patients with cirrhosis.

The efficacy and safety of peginterferon alfa-2a in patients with HCV-related cirrhosis or bridging fibrosis was examined by an international team.

271 patients with cirrhosis or bridging fibrosis were randomly assigned to receive subcutaneous treatment with 3 million units of interferon alfa-2a three times weekly (88 patients), 90 µg of peginterferon alfa-2a once weekly (96), or 180 µg of peginterferon alfa-2a once weekly (87).

Treatment lasted 48 weeks and was followed by a 24-week follow-up period.

Efficacy was assessed by measuring HCV RNA and alanine aminotransferase and by evaluating liver-biopsy specimens. A histologic response was defined as a decrease of at least 2 points on the 22-point Histological Activity Index.

In an intention-to-treat analysis, HCV RNA was found to be undetectable at week 72 in 8 per cent, 15 per cent, and 30 per cent of the patients treated with interferon alfa-2a and with 90 µg and 180 µg of peginterferon alfa-2a, respectively. At week 72, alanine aminotransferase concentrations had normalized in 15 per cent, 20 per cent, and 34 per cent of patients, respectively.

In the subgroup of 184 patients with paired liver-biopsy specimens, the rates of histologic response at week 72 were 31 per cent, 44 per cent, and 54 per cent, respectively. All three treatments were similarly tolerated.

Dr Jenny Heathcote concluded on behalf of the group that, "In patients with chronic hepatitis C and cirrhosis or bridging fibrosis, 180 µg of peginterferon alfa-2a administered once weekly is significantly more effective than 3 million units of standard interferon alfa-2a administered three times weekly." <<P> N Engl J Med 2000; 343: 1673-80
07 December 2000

Home | What is HCV | Transmission | Future | Complications | Biopsy | Treatment | Lab | Nutrition | Patient | Links | Transplant | Webrings | guestbookbook | Awards | FAQ |